International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a global organization comprising…
Expert article
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a global organization comprising regulatory authorities and pharmaceutical industry associations that collaborates to develop harmonized technical guidelines and requirements for the research, development, manufacturing, registration, and post-approval monitoring of medicines for human use. Founded in 1990 as the International Conference on Harmonisation through an initiative hosted by the European Federation of Pharmaceutical Industries and Associations (EFPIA) in Brussels, involving representatives from the European Community, Japan, and the United States, ICH transitioned into a formal legal entity under Swiss law on October 23, 2015, to expand its global reach and sustainability.
ICH's core mission is to promote public health by achieving greater international harmonization of technical standards, thereby reducing redundant clinical trials, minimizing development costs, and facilitating efficient access to innovative, safe, and effective medicines worldwide. Its guidelines are adopted and implemented by ICH members and observers in their respective regions, influencing regulatory frameworks in over 50 countries.
Governed by an Assembly that includes equal representation from regulatory authorities and industry, ICH has, as of 2025, 23 members—such as the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and industry bodies like the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)—along with 41 observers, including the World Health Organization (WHO) and additional national regulators. Over its more than 30 years, ICH has produced more than 50 guidelines, significantly streamlining global pharmaceutical regulation and supporting the industry's shift toward innovative therapies like biologics and advanced therapies.
Background
Purpose and Objectives
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) aims to achieve greater harmonization worldwide in the interpretation and application of technical guidelines and requirements for pharmaceutical product registration, ensuring that safe, effective, and high-quality medicines are developed and registered in the most efficient and cost-effective manner. This core purpose promotes public health by establishing common international standards that streamline the global regulatory landscape for pharmaceuticals.
Key objectives of ICH include reducing or obviating the duplication of clinical trials in humans and post-market evaluations, as well as minimizing the use of animal testing, all while maintaining rigorous standards for safety, quality, and efficacy. By standardizing technical requirements across regions, ICH enhances the overall process of drug development, manufacturing, registration, and supervision, thereby saving resources and accelerating the availability of new therapies without unnecessary repetition of studies.
The scope of ICH is specifically limited to human pharmaceuticals, focusing on technical aspects such as quality, safety, efficacy, and multidisciplinary topics like the Common Technical Document (CTD) format. It excludes areas outside these technical domains, such as pricing mechanisms, approvals for manufacturing sites, or environmental regulatory concerns, to maintain a targeted approach to harmonization.
Ultimately, ICH's efforts are vital for facilitating global access to innovative therapies by aligning regulatory expectations among participating authorities and industry stakeholders, thereby revolutionizing the efficiency of international pharmaceutical oversight and benefiting patients worldwide.
Founding
The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) was born in April 1990 during a meeting hosted by the European Federation of Pharmaceutical Industries and Associations (EFPIA) in Brussels. This gathering brought together representatives from major regulatory authorities and pharmaceutical industry associations to address the inefficiencies arising from divergent technical requirements across Europe, Japan, and the United States, which had led to duplicated efforts in drug development and registration.
The founding members included three regulatory authorities—the European Commission representing the European Communities, Japan's Ministry of Health and Welfare, and the United States Food and Drug Administration (FDA)—along with three industry associations: EFPIA, the Japan Pharmaceutical Manufacturers Association (JPMA), and the Pharmaceutical Research and Manufacturers of America (PhRMA). The European Free Trade Association (EFTA) participated as an observer from the outset.
ICH's initial focus centered on harmonizing key aspects of pharmaceutical technical requirements, including safety, quality, efficacy, and multidisciplinary topics, to facilitate more efficient global drug development while maintaining regulatory standards. This effort aimed to reduce redundancies, such as duplicated clinical trials, thereby accelerating access to innovative medicines.
The first formal ICH conference convened in Brussels in 1991, marking the beginning of guideline development. Early outcomes included the adoption of foundational guidelines, such as the stability testing guideline (ICH Q1A) in 1993, which provided standardized protocols for assessing drug substance and product stability.
History
Early Developments (1990–2014)
The International Conference on Harmonisation (ICH), established in 1990, initially operated through ad hoc meetings among regulatory authorities and pharmaceutical industry representatives from Europe, Japan, and the United States to address inconsistencies in technical requirements for drug approval. These early efforts evolved into a more structured framework with the organization of triennial conferences, beginning with the first ICH conference in Brussels in 1991 and continuing through the ninth in Washington, D.C., in 2013. This progression allowed for systematic consensus-building on harmonized standards, culminating in the production of over 50 guidelines by 2014 across key areas: Quality (Q) guidelines focusing on pharmaceutical development and manufacturing, Safety (S) guidelines addressing nonclinical testing and toxicology, and Efficacy (E) guidelines concerning clinical trials and evaluation.
A pivotal milestone was the introduction of the Common Technical Document (CTD) in 2000 during the fifth ICH conference, which established a unified format for compiling technical dossiers for drug marketing applications, streamlining submissions and reducing administrative burdens for sponsors. Additionally, in 2003, the World Health Organization (WHO) was welcomed as an observer, broadening ICH's scope to support global dissemination and adaptation of guidelines in developing regions. These developments were driven by the need to reconcile regional differences in testing protocols, such as varying requirements for stability data or preclinical studies, which previously necessitated duplicate animal and clinical testing to meet divergent standards in the US, EU, and Japan. By harmonizing these requirements, ICH guidelines significantly curtailed redundant research, saving resources and accelerating drug development while upholding safety and efficacy.
By 2014, the cumulative impact of these early efforts was evident in widespread adoption: regulatory agencies in Europe (via the European Medicines Agency), Japan (via the Pharmaceuticals and Medical Devices Agency), and the United States (via the Food and Drug Administration) had fully integrated ICH guidelines into their frameworks, with Canada (Health Canada) and Switzerland (Swissmedic) increasingly aligning their processes as observers. This harmonization not only facilitated mutual recognition of data but also enhanced international collaboration, enabling faster access to innovative medicines without compromising public health standards.
2015 Reform
In 2014, discussions on reforming the International Conference on Harmonisation (ICH) were initiated to address the need for a more permanent and globally inclusive structure, building on the successes of its early guidelines that had facilitated harmonized pharmaceutical development over 25 years. These reforms culminated in the official establishment of the ICH as a Swiss non-profit association on October 23, 2015, transitioning it from an informal conference model to a formal legal entity under Swiss law. This change aimed to enhance the organization's long-term viability and adaptability to evolving global regulatory landscapes.
Key structural modifications included the creation of the ICH Assembly as the supreme governing body, responsible for strategic oversight and decision-making by consensus among its members. The reform also shifted the membership model from the original six founding parties—regulators and industry associations from Europe, Japan, and the United States—to a broader framework that incorporated additional regulators and industry representatives from regions such as Canada and Switzerland, with provisions for further expansion. Funding mechanisms were updated to rely on membership fees, reducing dependence on industry contributions and promoting financial independence. These alterations distinguished the decision-making roles of regulators from those of industry while improving transparency through enhanced public reporting on activities.
The primary objectives of the 2015 reform were to increase inclusivity by engaging emerging markets and non-traditional stakeholders, formalize governance processes for more efficient harmonization, and ensure sustainability amid growing demands for global regulatory convergence in pharmaceutical development. By broadening participation, the reform sought to better reflect the international nature of drug innovation and regulation, ultimately benefiting patients through faster access to safe and effective medicines.
The inaugural ICH Assembly convened on October 23, 2015, coinciding with the association's establishment, where members adopted revised terms of reference to guide the organization's operations under the new structure. This meeting marked the operational launch of the reformed ICH, setting the stage for enhanced collaboration on technical guidelines.
Expansion and Recent Milestones (2016–2025)
Following the 2015 reform, which enabled broader participation beyond the original six founding parties (three regulatory authorities—EC, FDA, and MHLW/PMDA—and three industry associations—EFPIA, JPMA, and PhRMA), the ICH experienced significant membership growth, expanding from these initial entities to 23 members by 2025. This expansion included key regulatory additions such as Brazil's ANVISA in November 2016, China's NMPA in June 2017, South Korea's MFDS in 2016, and Singapore's HSA in November 2017, reflecting ICH's increasing global reach to harmonize pharmaceutical standards in emerging markets.
Observer status also proliferated during this period, reaching 41 by May 2025, with notable 2025 additions including Paraguay's DINAVISA, Kuwait's MOH, and El Salvador's SRS, enhancing ICH's consultative network across Latin America and the Middle East. These developments underscored ICH's strategy to incorporate diverse regulatory perspectives for more inclusive guideline development.
Key milestones included the adoption of the ICH E6(R3) Good Clinical Practice guideline on January 6, 2025, which modernized standards for clinical trials to address contemporary challenges like decentralized and pragmatic designs. In May 2025, during the ICH Assembly meeting in Madrid, Spain (May 13–14), the organization announced new topics for guideline development: considerations for the use of real-world evidence to inform regulatory decision-making, utility of comparative efficacy studies in biosimilar development, natural history studies for rare disease drug development, and principles for real-world data studies in safety evaluation. Later in 2025, ICH adopted the M14 guideline on September 4 for planning and reporting real-world data safety studies. The biannual Assembly meetings, formalized since 2015, continued to drive these advancements, with the next event scheduled for November 18–19, 2025, in Singapore.
Organizational Structure
Governing Bodies
The ICH Assembly serves as the supreme governing body of the organization, comprising one representative from each ICH Member—both regulatory authorities and industry associations—as well as standing observers such as the World Health Organization (WHO) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). It meets twice annually to make key decisions, including the approval of ICH guidelines, initiation of new harmonization topics, admission of new members and observers, and amendments to the Articles of Association and Rules of Procedure. This structure ensures broad consensus on strategic direction, with the Assembly acting as the ultimate authority for endorsing technical documents and overseeing the organization's global expansion.
The Management Committee (MC) functions as the operational oversight body, coordinating day-to-day activities, administrative and financial matters, and the work of various expert groups while submitting recommendations to the Assembly for final approval. It consists of 14 regulatory and industry representatives from founding members (European Commission, European Federation of Pharmaceutical Industries and Associations, U.S. Food and Drug Administration, Japan Pharmaceutical Manufacturers Association, Ministry of Health, Labour and Welfare/Pharmaceuticals and Medical Devices Agency of Japan, and Pharmaceutical Research and Manufacturers of America), standing members (Health Canada and Swissmedic), and elected representatives from additional regions such as Brazil's ANVISA, China's NMPA, and Korea's MFDS, along with two standing observers. The MC, chaired by a regulatory representative (currently Dr. Theresa Mullin from the FDA), monitors progress on guideline development, publishes meeting minutes, and ensures alignment across regions, with its composition reflecting the 2015 reform's emphasis on inclusivity.
Expert Working Groups (EWGs) are the technical core of ICH's decision-making, comprising multidisciplinary teams of 6 to 10 experts per topic, drawn from regulatory authorities and industry representatives appointed by ICH Members, to develop and refine harmonization guidelines through scientific consensus. These groups, typically involving over 700 experts across 32 active working groups, operate under the oversight of the MC and a designated rapporteur from a Member authority, focusing on specific areas like quality, safety, efficacy, and multidisciplinary standards. EWGs follow a structured process to draft technical documents, incorporating input from members and observers to address global pharmaceutical challenges, with their outputs advancing to higher governing levels for endorsement.
The ICH Secretariat provides essential administrative support, managing daily operations, coordinating meetings and communications, and facilitating the activities of the Assembly, MC, EWGs, and the separate MedDRA Management Committee from its base in Geneva, Switzerland. Funded primarily through annual membership fees approved by the Assembly, the Secretariat handles logistics, document publication, and stakeholder engagement to ensure efficient implementation of ICH's harmonization efforts.
Members
The International Council for Harmonisation (ICH) comprises 23 full voting members as of 2025, divided into 17 regulatory authorities and 6 industry associations, each representing significant pharmaceutical markets worldwide. These members participate actively in the development and adoption of harmonized technical standards for pharmaceuticals, ensuring balanced input from both regulatory and industry perspectives. Membership criteria require regulatory authorities to hold legal responsibility for medicines regulation in their jurisdictions and to demonstrate substantial market influence, while industry associations must represent the pharmaceutical sector in corresponding regions or internationally.
Each of the 23 members holds equal voting rights in the ICH Assembly, with one vote per member, promoting equitable decision-making on strategic and policy matters. This structure reflects ICH's evolution since its 2015 reform, which expanded membership to include more diverse global stakeholders while maintaining the founding principles of collaboration. Recent additions from emerging markets have further broadened representation, incorporating authorities from regions like Africa and Asia-Pacific.
Regulatory Members
The 17 regulatory members are responsible for overseeing pharmaceutical safety, efficacy, and quality in their respective jurisdictions. They include both founding and later-admitted authorities, with some jurisdictions featuring dual representation for comprehensive expertise. The following table lists them with acronyms and countries/regions:
| Acronym/Name | Full Name | Country/Region |
|---|---|---|
| EC/EMA | European Commission / European Medicines Agency | European Union |
| FDA | U.S. Food and Drug Administration | United States |
| MHLW/PMDA | Ministry of Health, Labour and Welfare / Pharmaceuticals and Medical Devices Agency | Japan |
| Health Canada | Health Canada | Canada |
| Swissmedic | Swiss Agency for Therapeutic Products | Switzerland |
| ANVISA | National Health Surveillance Agency | Brazil |
| NMPA | National Medical Products Administration | China |
| MFDS | Ministry of Food and Drug Safety | South Korea |
| TGA | Therapeutic Goods Administration | Australia |
| Medsafe | Medicines and Medical Devices Safety Authority | New Zealand |
| HSA | Health Sciences Authority | Singapore |
| TFDA | Taiwan Food and Drug Administration | Taiwan |
| SAHPRA | South African Health Products Regulatory Authority | South Africa |
| ANMAT | National Administration of Drugs, Foods and Medical Devices | Argentina |
| COFEPRIS | Federal Commission for the Protection against Sanitary Risk | Mexico |
| SFDA | Saudi Food and Drug Authority | Saudi Arabia |
| TITCK | Turkish Medicines and Medical Devices Agency | Turkey |
This composition ensures coverage of major global markets, from established economies to rapidly growing ones.
Industry Members
The 6 industry associations provide expertise on manufacturing, research, and development practices, often mirroring the regulatory members' regional focus. They include the three founding associations alongside international and regional groups to align with ICH's expanded scope. Key examples include:
- EFPIA (European Federation of Pharmaceutical Industries and Associations), representing Europe.
- PhRMA (Pharmaceutical Research and Manufacturers of America), representing the United States.
- JPMA (Japan Pharmaceutical Manufacturers Association), representing Japan.
- BIO (Biotechnology Innovation Organization), providing international perspective on biologics.
- PhIRDA (Pharmaceutical Innovation and Research Development Association) for China.
- Interfarma (Associação da Indústria Farmacêutica de Pesquisa) for Brazil, KPMA (Korea Pharmaceutical Manufacturers Association) for South Korea, and Medicines Australia for Australia, among others corresponding to additional regulatory members.
These associations facilitate industry input into guideline development, ensuring practical applicability across diverse markets.
Observers
Observers in the International Council for Harmonisation (ICH) serve as non-voting participants that provide valuable input during the development of guidelines, ensuring diverse perspectives from global health organizations and regulatory authorities in emerging markets. They attend ICH meetings, contribute expertise to expert working groups, and help align harmonization efforts with broader international needs, without holding decision-making or voting rights. This advisory role promotes inclusivity and facilitates the adoption of ICH standards in regions beyond core members.
ICH designates two standing observers: the World Health Organization (WHO), which offers insights on global public health implications, and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), which represents industry views and overlaps with some ICH member organizations. In addition to these, regional observers include regulatory authorities from various countries, such as the Central Drugs Standard Control Organization (CDSCO) from India, Roszdravnadzor from Russia, and others that bring regional regulatory challenges to the table.
As of May 2025, ICH has 41 observers in total, encompassing standing entities, regional harmonization initiatives, and individual regulatory authorities, which indirectly represent input from over 50 countries. Recent expansions in 2025 welcomed new observers including the State Service on Medicines and Medical Devices (CPPS) from Uzbekistan, the General Directorate of Medicines, Supplies and Drugs (DIGEMID) from Peru, the National Drug Directorate (DINAVISA) from Paraguay, the Ministry of Health (MOH) from Kuwait, and the Regulatory Health Authority (SRS) from El Salvador. These additions enhance the global reach of ICH guidelines by incorporating perspectives from diverse economic and geographic contexts.
The inclusion of observers strengthens the applicability of ICH work products in non-member regions by addressing implementation barriers early and fostering international collaboration, ultimately supporting safer and more efficient pharmaceutical development worldwide.
Harmonization Process
Step 1: Consensus Building
The consensus building phase, designated as Step 1 in the ICH harmonization process, represents the foundational expert-driven stage where technical specialists from regulatory authorities and industry collaborate to draft initial guideline proposals. This step ensures that scientific and technical aspects of pharmaceutical development are aligned across ICH regions by focusing on evidence-based discussions and iterative refinements.
Initiation of Step 1 occurs following the ICH Assembly's endorsement of a Concept Paper and Business Plan for a new harmonization topic, which outlines the objectives, scope, and rationale. Subsequently, an Expert Working Group (EWG) is established, comprising nominated technical experts from ICH members, along with observers where applicable; the group includes a Rapporteur from the region originating the proposal and a Regulatory Chair appointed by an ICH Management Committee member to oversee proceedings. The EWG's formation is approved by the Management Committee, enabling the group to commence work on developing a consensus draft technical document aligned with the Concept Paper's goals.
During this phase, EWG members engage in detailed discussions of scientific issues, leveraging existing data, regulatory experiences, and identified needs to draft and revise the technical document. The process emphasizes achieving agreement on core concepts through collaborative review, with the Rapporteur circulating initial drafts for comments via email, teleconferences, and web conferences; face-to-face meetings occur during biannual ICH Assembly sessions if authorized by the Management Committee. Progress is regularly reported to the ICH Assembly by the Regulatory Chair and Rapporteur, with any delays or challenges in reaching consensus escalated for resolution. This expert-level deliberation typically spans 12–18 months, allowing sufficient time for thorough analysis while maintaining momentum toward harmonization.
The output of Step 1 is a finalized consensus draft technical document, signed off by the EWG Topic Leaders (or their alternates) on a dedicated sign-off sheet to confirm expert agreement. This document is then submitted to the ICH Assembly, marking the transition to subsequent phases and serving as the basis for broader regulatory alignment in pharmaceutical standards.
Step 2: Confirmation and Endorsement
Following the consensus building by the Expert Working Group in Step 1, Step 2 of the ICH harmonization process—Confirmation and Endorsement—focuses on validating the technical document and draft guideline at the leadership level to ensure they reflect scientific agreement, regional regulatory priorities, and practical applicability before advancing to wider consultation. This step is divided into two subphases, 2a and 2b, conducted through the ICH Assembly and Regulatory Members, respectively, with the Management Committee providing oversight and recommendations.
In Step 2a, the Management Committee reviews the Expert Working Group's report on the technical document and recommends its endorsement to the ICH Assembly, which comprises representatives from both Regulatory Members and Industry Associations. The Assembly confirms that the document aligns with regional needs and achieves sufficient scientific consensus, endorsing it as the final Technical Document either during a face-to-face meeting or via written procedure; this endorsement requires consensus among members, or a majority vote if needed. This phase ensures the content is robust and suitable for progression, with the Management Committee facilitating resolution of any identified issues.
Step 2b shifts to the Regulatory Members of the Assembly, who develop and endorse the draft Guideline based on the endorsed Technical Document from Step 2a, verifying its feasibility for implementation across regions. Industry Associations, having contributed through the Assembly in Step 2a, provide input on practical aspects such as resource requirements and industry-wide applicability, helping to affirm the draft's viability without formal voting rights in this subphase. The endorsement occurs similarly by consensus or majority vote among Regulatory Members, resulting in the draft being designated as the Step 2b Guideline and prepared for public release on the ICH website.
The joint sign-off in Step 2 culminates in agreement between Regulatory Members and Industry Associations on the finalized Step 2 document, with any discrepancies resolved through Management Committee mediation to produce a unified version ready for the next stage. This collaborative validation typically spans 3–6 months, allowing time for reviews and iterations while minimizing delays to maintain momentum in the overall harmonization timeline.
Step 3: Regulatory Consultation
Following the endorsement at Step 2b, the draft guideline enters Step 3, where it is circulated to all ICH regulatory members for comprehensive review and comment.
This circulation process involves distributing the document to regulators in ICH regions, such as the European Union, Japan, the United States, and others, who then solicit feedback from stakeholders within their jurisdictions, typically allowing a 3–6 month period for submissions.
Regulators compile and submit written comments through the ICH Secretariat, with any unresolved issues escalated for discussion at meetings of the ICH Management Committee or Assembly to facilitate dialogue among representatives.
The primary goal of this phase is to secure broad agreement among all regulatory members on the guideline's implications for pharmaceutical regulation, ensuring alignment across diverse regional perspectives.
Upon reaching consensus, the output is a revised Step 3 Experts Draft Guideline if modifications are required, which is then signed off by regulatory experts and advanced to Step 4 for adoption; no revisions occur if full agreement is already achieved.
Step 4: Adoption
Step 4 of the ICH harmonization process involves the adoption of the guideline by the ICH Assembly, marking it as an officially harmonized document ready for implementation by member regulatory authorities. At this stage, the final draft from Step 3, known as the Step 3 Expert Guideline, is presented to the Assembly for review and approval. The Assembly, comprising representatives from regulatory members and industry, evaluates whether sufficient scientific consensus has been achieved based on the consultations and feedback incorporated in the prior step.
Adoption requires agreement among all ICH regulatory members, ensuring that the guideline reflects a unified international standard without the need for further revisions. Upon reaching consensus, the Assembly formally adopts the document as an ICH Harmonised Guideline, typically through a vote or unanimous approval during an Assembly meeting. This step solidifies the guideline's status, distinguishing it from earlier drafts by granting it binding harmonization authority across ICH regions.
The effective date of adoption occurs immediately upon Assembly approval, at which point the guideline is designated as final and harmonized. A recent example is the E6(R3) Guideline on Good Clinical Practice, which was adopted by the ICH Assembly on January 6, 2025, following consensus on its revisions to address modern clinical trial complexities.
Following adoption, the guideline is promptly published on the official ICH website, making it publicly accessible and signaling its readiness for application. ICH members, including regulatory authorities, commit to incorporating the harmonized guideline into their national or regional frameworks, thereby promoting global consistency in pharmaceutical standards. This commitment underscores the guideline's role in facilitating efficient drug development and approval processes worldwide.
Step 5: Implementation
Following adoption at Step 4, ICH guidelines enter the implementation phase, where regulatory members and observers incorporate them into their national or regional regulatory frameworks, such as laws, guidance documents, or mandatory requirements for pharmaceutical development and approval. This transposition process ensures that harmonized standards are applied consistently within each jurisdiction, though the guidelines themselves remain non-binding internationally. For example, the U.S. Food and Drug Administration (FDA) typically publishes ICH guidelines as final guidance within 1-2 years of ICH endorsement, as seen with the ICH E6(R3) Good Clinical Practice guideline adopted in January 2025 and issued by the FDA in September 2025. Similarly, the European Medicines Agency (EMA) often implements guidelines more rapidly, with E6(R3) becoming effective in the EU on July 23, 2025.
The ICH monitors implementation through independent third-party surveys conducted periodically among its members and observers, assessing both adoption rates and adherence in practice; these efforts are essential for maintaining membership expectations under the ICH Articles of Association, even though compliance is not legally enforced. Surveys in 2019, 2021, and 2024 revealed increasing implementation, with an average of 73% for select Tier 2 guidelines among non-founding members in 2024, up from 47% in 2019, highlighting progress but also gaps in full adherence. Regulators submit self-declarations, supplemented by industry feedback, to identify areas needing support, such as training or clarification on guideline application.
Challenges in implementation often arise from the need to adapt guidelines to local legal, cultural, and resource contexts, particularly in emerging markets where regulatory capacities may be limited and domestic priorities differ. For instance, non-founding members like those in Brazil and China reported lower adherence rates for certain guidelines, such as Q12 on lifecycle management (10% implementation and 0% adherence among non-founding non-standing members in 2024), due to integration hurdles with existing systems and resource constraints. These issues can lead to delayed or partial adoption, though ICH supports mitigation through capacity-building initiatives.
By 2025, ICH guidelines have achieved broad global reach, with over 50 countries referencing them in their regulatory processes, frequently through collaboration with the World Health Organization (WHO), which promotes their use in prequalification programs and national medicines regulation in low- and middle-income countries. This widespread adoption enhances international consistency in pharmaceutical standards while allowing flexibility for regional variations.
Guidelines and Work Products
Guideline Categories
The International Council for Harmonisation (ICH) organizes its guidelines into four primary categories: Quality (Q), Safety (S), Efficacy (E), and Multidisciplinary (M). These categories reflect the technical areas addressed in pharmaceutical development and regulation, encompassing over 78 guidelines developed by 2025, including core documents and their revisions. The guidelines emerge from the ICH harmonization process, which ensures consistent standards across regulatory authorities.
Quality (Q) Guidelines
Quality guidelines focus on pharmaceutical development, manufacturing, and quality control to ensure product consistency, stability, and compliance with good manufacturing practices. There are 15 such guidelines, addressing aspects like stability testing, impurities, and risk management. The key guidelines in the Q series include:
- Q1A(R2)–Q1E: Stability Testing, providing recommendations on protocols for evaluating the stability of new drug substances and products under various conditions.
- Q2(R2): Validation of Analytical Procedures, outlining principles and methodologies for validating analytical methods used in pharmaceutical testing.
- Q3A(R2)–Q3E: Impurities, addressing the identification, reporting, and qualification of impurities in new drug substances and products, including residual solvents and elemental impurities.
- Q5A(R2)–Q5E: Quality of Biotechnological/Biological Products, covering aspects such as viral safety, comparability of biotechnological products, and quality issues specific to biological entities.
- Q6A–Q6B: Specifications for Chemical and Biotechnological Products, establishing test procedures and acceptance criteria for new drug substances and products.
- Q7: GMP for Active Pharmaceutical Ingredients (APIs), providing guidance on good manufacturing practices for the production of APIs.
- Q8(R2): Pharmaceutical Development (Quality by Design – QbD), outlining principles for a science- and risk-based approach to product development.
- Q9(R1): Quality Risk Management, providing a systematic process for assessing, controlling, and communicating risks associated with pharmaceutical quality.
- Q10: Pharmaceutical Quality System, describing an effective quality system for the lifecycle of a pharmaceutical product.
- Q11: Development and Manufacture of Drug Substances, offering approaches to developing and understanding the manufacturing process for drug substances, both chemical and biotechnological.
- Q12: Lifecycle Management (post-approval changes), providing a framework for managing post-approval changes to pharmaceutical products.
- Q13: Continuous Manufacturing, describing scientific approaches and regulatory considerations for continuous manufacturing of drug substances and products.
- Q14: Analytical Procedure Development, harmonizing scientific approaches to the development of analytical procedures.
Representative examples include Q8 on Pharmaceutical Development, which outlines principles for a science- and risk-based approach to product development; Q9 on Quality Risk Management, providing a systematic process for assessing, controlling, and communicating risks; and Q10 on Pharmaceutical Quality System, describing an effective quality system for the lifecycle of a pharmaceutical product.
Safety (S) Guidelines
Safety guidelines pertain to non-clinical testing and evaluation to identify potential risks to human health, such as toxicity and genotoxicity. Comprising 11 guidelines, they guide the design and interpretation of preclinical studies. Key examples are S1 on Carcinogenicity Studies, which specifies requirements for assessing carcinogenic potential in pharmaceuticals; S9 on Nonclinical Evaluation for Anticancer Pharmaceuticals, offering an alternative approach for oncology drugs with reduced non-clinical data needs; and S7A on Safety Pharmacology Studies for Human Pharmaceuticals, recommending core battery studies to evaluate effects on vital organ systems.
Efficacy (E) Guidelines
Efficacy guidelines cover clinical studies, pharmacovigilance, and statistical principles to support the demonstration of a drug's benefits in human trials. With 19 guidelines in this category, they emphasize ethical conduct, data management, and population-specific considerations. Notable examples include E2 on Pharmacovigilance Planning, detailing strategies for monitoring safety during and after clinical development; E6 on Good Clinical Practice, establishing standards for trial design, conduct, and reporting; and E11 on Pediatric Extrapolation, guiding the extrapolation of efficacy data from adults to children.
Multidisciplinary (M) Guidelines
Multidisciplinary guidelines address cross-cutting topics that span multiple areas, such as documentation formats and impurity controls not confined to one category. There are 11 such guidelines, facilitating global regulatory submissions and data exchange. Examples include M4 on the Common Technical Document, standardizing the organization of regulatory submissions; M7 on Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals, providing a framework for identifying and limiting mutagenic impurities; and M8 on Electronic Common Technical Document, supporting digital submission standards.
In total, ICH has established approximately 56 core guidelines across these categories by 2025, with additional revisions and updates expanding the set to over 78 documents, excluding separate work products like MedDRA.
Key Examples and Revisions
One of the foundational ICH guidelines is the Common Technical Document (CTD) under M4, which established a standardized format for organizing regulatory submissions for pharmaceuticals, including modules for quality, safety, efficacy, and administrative data; it was adopted in 2000 to facilitate global submissions. Subsequent revisions have refined specific sections, such as M4Q(R1) for the quality module, which details the structure for drug substance and product information, and M4S(R2) for the nonclinical safety overview and summaries, improving clarity and consistency in safety data presentation. These updates, including the draft 2025 revision M4Q(R2) under public consultation, which proposes expanding applicability to all pharmaceutical drug products, aim to streamline dossier preparation and review processes across regions.
The Quality by Design (QbD) series, encompassing ICH Q8(R2) through Q12, introduces principles for designing quality into pharmaceutical development and manufacturing, allowing for science- and risk-based flexibility rather than rigid specifications. Q8(R2) focuses on pharmaceutical development to ensure product performance, Q9(R1) on quality risk management tools, Q10 on pharmaceutical quality systems for lifecycle control, Q11 on development and manufacture of drug substances including biotechnological entities, and Q12, adopted in 2019, on technical and regulatory considerations for product lifecycle management to support post-approval changes without extensive re-submissions. This framework has enabled innovative manufacturing approaches, such as continuous processing, while addressing evolving biotechnological complexities.
In the efficacy domain, the Good Clinical Practice (GCP) guideline ICH E6(R3), finalized in January 2025, updates standards for clinical trial conduct with an emphasis on risk-based monitoring, quality by design principles, and integration of digital tools to enhance efficiency and data integrity. It expands beyond traditional trials to incorporate modern elements like electronic systems and diverse data sources, while maintaining ethical protections for participants. In September 2025, the ICH E2D(R1) guideline was adopted, updating standards for post-approval individual case safety reporting.
These key guidelines, including CTD, QbD, and GCP, have collectively harmonized requirements across ICH regions, substantially reducing duplicative clinical studies and expediting drug approvals by preventing redundant testing and aligning evaluation criteria. Revisions reflect advancements in science, such as biotechnological products in Q11 and emerging technologies like AI-assisted trial monitoring in E6(R3).
In 2025, ICH advanced guidelines on real-world evidence through M14, which provides harmonized principles for planning, designing, analyzing, and reporting pharmacoepidemiological studies using real-world data for post-marketing safety assessments, including digital health technologies like sensors and software. This builds on E6(R3)'s provisions for digital data in trials, promoting broader use of non-interventional data to inform regulatory decisions efficiently.
MedDRA
The Medical Dictionary for Regulatory Activities (MedDRA) is a standardized international medical terminology developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) to support the sharing of regulatory information for medical products used by humans, including pharmaceuticals, biologics, and vaccines. Launched in 1997 following approval by the ICH Steering Committee, MedDRA facilitates consistent classification, retrieval, and analysis of safety data across regulatory authorities and the pharmaceutical industry. It is maintained and distributed by the Maintenance and Support Services Organization (MSSO), which operates under ICH oversight through a contract currently held by Peraton, ensuring ongoing development and global accessibility.
MedDRA employs a five-level hierarchical structure to organize medical terms, enabling precise coding of clinical data: System Organ Class (SOC) at the top level, followed by High Level Group Term (HLGT), High Level Term (HLT), Preferred Term (PT), and Lowest Level Term (LLT). This hierarchy encompasses 27 SOCs, such as "Infections and infestations" and "Gastrointestinal disorders," covering a wide range of applications including adverse events, indications, investigations, and product issues. The terminology is designed for use in both pre- and post-marketing phases, promoting harmonized reporting and analysis of medical information without altering the underlying clinical data.
MedDRA receives annual updates to incorporate emerging medical concepts and improve usability, with Version 28.0 released on March 1, 2025, for English and mid-March for other supported languages. This version introduced modifications such as new and updated terms for contemporary therapies, including coded enhancements for gene therapy applications, alongside 289 PT changes derived from 1,620 change requests. In ICH regions, MedDRA is mandatory for pharmacovigilance reporting under standards like ICH E2B(R3), which specifies its use for electronic transmission of individual case safety reports. Access is provided free of charge to regulatory authorities and non-commercial users, while industry subscribers obtain licenses based on company revenue, supporting widespread adoption.
Although not classified as an ICH guideline, MedDRA functions as a key ICH work product, with strategic direction provided by the ICH MedDRA Steering Committee to align it with evolving regulatory needs. It integrates briefly with ICH efficacy and safety guidelines, such as those in the E2 series, by standardizing terminology for adverse event reporting in clinical trials and post-approval surveillance.
By the Factrail desk · Method: how we source and score · Last reviewed